Losson R, Lacroute F: Interference of nonsense mutations with eukaryotic messenger RNA stability. Proc Natl Acad Sci U S A. 1979, 76: 5134-5137.
Lim S, Mullins JJ, Chen CM, Gross KW, Maquat LE: Novel metabolism of several beta zero-thalassemic beta-globin mRNAs in the erythroid tissues of transgenic mice. Embo J. 1989, 8: 2613-2619.
Maquat LE, Kinniburgh AJ, Rachmilewitz EA, Ross J: Unstable beta-globin mRNA in mRNA-deficient beta o thalassemia. Cell. 1981, 27: 543-553. 10.1016/0092-8674(81)90396-2
Chang JC, Kan YW: beta 0 thalassemia, a nonsense mutation in man. Proc Natl Acad Sci U S A. 1979, 76: 2886-2889.
Frischmeyer PA, Dietz HC: Nonsense-mediated mRNA decay in health and disease. Hum Mol Genet. 1999, 8: 1893-1900. 10.1093/hmg/8.10.1893
He F, Peltz SW, Donahue JL, Rosbash M, Jacobson A: Stabilization and ribosome association of unspliced pre-mRNAs in a yeast upf1- mutant. Proc Natl Acad Sci U S A. 1993, 90: 7034-7038.
Li S, Wilkinson MF: Nonsense surveillance in lymphocytes?. Immunity. 1998, 8: 135-141. 10.1016/S1074-7613(00)80466-5
Lozano F, Maertzdorf B, Pannell R, Milstein C: Low cytoplasmic mRNA levels of immunoglobulin kappa light chain genes containing nonsense codons correlate with inefficient splicing. Embo J. 1994, 13: 4617-4622.
Morrison M, Harris KS, Roth MB: smg mutants affect the expression of alternatively spliced SR protein mRNAs in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1997, 94: 9782-9785. 10.1073/pnas.94.18.9782
Mitrovich QM, Anderson P: Unproductively spliced ribosomal protein mRNAs are natural targets of mRNA surveillance in C. elegans. Genes Dev. 2000, 14: 2173-2184. 10.1101/gad.819900
Hillman RT, Green RE, Brenner SE: An unappreciated role for RNA surveillance. Genome Biol. 2004, 5: R8- 10.1186/gb-2004-5-2-r8
Wollerton MC, Gooding C, Wagner EJ, Garcia-Blanco MA, Smith CW: Autoregulation of polypyrimidine tract binding protein by alternative splicing leading to nonsense-mediated decay. Mol Cell. 2004, 13: 91-100. 10.1016/S1097-2765(03)00502-1
Wilson GM, Sun Y, Sellers J, Lu H, Penkar N, Dillard G, Brewer G: Regulation of AUF1 expression via conserved alternatively spliced elements in the 3' untranslated region. Mol Cell Biol. 1999, 19: 4056-4064.
Lamba JK, Adachi M, Sun D, Tammur J, Schuetz EG, Allikmets R, Schuetz JD: Nonsense mediated decay downregulates conserved alternatively spliced ABCC4 transcripts bearing nonsense codons. Hum Mol Genet. 2003, 12: 99-109. 10.1093/hmg/ddg011
Sureau A, Gattoni R, Dooghe Y, Stevenin J, Soret J: SC35 autoregulates its expression by promoting splicing events that destabilize its mRNAs. Embo J. 2001, 20: 1785-1796. 10.1093/emboj/20.7.1785
Menegay HJ, Myers MP, Moeslein FM, Landreth GE: Biochemical characterization and localization of the dual specificity kinase CLK1. J Cell Sci. 2000, 113 (Pt 18): 3241-3253.
Lewis BP, Green RE, Brenner SE: Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. Proc Natl Acad Sci U S A. 2003, 100: 189-192. 10.1073/pnas.0136770100
Modrek B, Lee C: A genomic view of alternative splicing. Nat Genet. 2002, 30: 13-19. 10.1038/ng0102-13
Stephenson LS, Maquat LE: Cytoplasmic mRNA for human triosephosphate isomerase is immune to nonsense-mediated decay despite forming polysomes. Biochimie. 1996, 78: 1043-1047. 10.1016/S0300-9084(97)86728-4
Mitchell GA, Grompe M, Lambert M, Tanguay RM: Hypertyrosinemia. The metabolic and molecular bases of inherited diseases. Edited by: Scriver CR, Beaudet AL, Sly WS and Valle D. 2001, 1777-1805. New York, McGraw-Hill, 8,
Poudrier J, Lettre F, Scriver CR, Larochelle J, Tanguay RM: Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes. Mol Genet Metab. 1998, 64: 119-125. 10.1006/mgme.1998.2695
Phaneuf D, Labelle Y, Berube D, Arden K, Cavenee W, Gagne R, Tanguay RM: Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15. Am J Hum Genet. 1991, 48: 525-535.
Labelle Y, Phaneuf D, Leclerc B, Tanguay RM: Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity. Hum Mol Genet. 1993, 2: 941-946.
St-Louis M, Tanguay RM: Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview. Hum Mutat. 1997, 9: 291-299. 10.1002/(SICI)1098-1004(1997)9:4<291::AID-HUMU1>3.0.CO;2-9
Arranz JA, Pinol F, Kozak L, Perez-Cerda C, Cormand B, Ugarte M, Riudor E: Splicing mutations, mainly IVS6-1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients. Hum Mutat. 2002, 20: 180-188. 10.1002/humu.10084
Heath SK, Gray RG, McKiernan P, Au KM, Walker E, Green A: Mutation screening for tyrosinaemia type I. J Inherit Metab Dis. 2002, 25: 523-524. 10.1023/A:1021275923668
Salo MK: [Tyrosinemia]. Duodecim. 1992, 108: 841-843.
St-Louis M, Leclerc B, Laine J, Salo MK, Holmberg C, Tanguay RM: Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I. Hum Mol Genet. 1994, 3: 69-72.
Dreumont N, Maresca A, Khandjian EW, Baklouti F, Tanguay RM: Cytoplasmic nonsense-mediated mRNA decay for a nonsense (W262X) transcript of the gene responsible for hereditary tyrosinemia, fumarylacetoacetate hydrolase. Biochem Biophys Res Commun. 2004, 324: 186-192. 10.1016/j.bbrc.2004.09.041
Dreumont N, Poudrier JA, Bergeron A, Levy HL, Baklouti F, Tanguay RM: A missense mutation (Q279R) in the fumarylacetoacetate hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation. BMC Genet. 2001, 2: 9- 10.1186/1471-2156-2-9
Cartegni L, Chew SL, Krainer AR: Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet. 2002, 3: 285-298. 10.1038/nrg775
Tanguay RM, Valet JP, Lescault A, Duband JL, Laberge C, Lettre F, Plante M: Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). Am J Hum Genet. 1990, 47: 308-316.
Grompe M, al-Dhalimy M: Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I. Hum Mutat. 1993, 2: 85-93.
Noensie EN, Dietz HC: A strategy for disease gene identification through nonsense-mediated mRNA decay inhibition. Nat Biotechnol. 2001, 19: 434-439. 10.1038/88099
Rootwelt H, Hoie K, Berger R, Kvittingen EA: Fumarylacetoacetase mutations in tyrosinaemia type I. Hum Mutat. 1996, 7: 239-243.
Takahara K, Schwarze U, Imamura Y, Hoffman GG, Toriello H, Smith LT, Byers PH, Greenspan DS: Order of intron removal influences multiple splice outcomes, including a two-exon skip, in a COL5A1 acceptor-site mutation that results in abnormal pro-alpha1(V) N-propeptides and Ehlers-Danlos syndrome type I. Am J Hum Genet. 2002, 71: 451-465. 10.1086/342099
Schwarze U, Starman BJ, Byers PH: Redefinition of exon 7 in the COL1A1 gene of type I collagen by an intron 8 splice-donor-site mutation in a form of osteogenesis imperfecta: influence of intron splice order on outcome of splice-site mutation. Am J Hum Genet. 1999, 65: 336-344. 10.1086/302512
Neu-Yilik G, Gehring NH, Hentze MW, Kulozik AE: Nonsense-mediated mRNA decay: from vacuum cleaner to Swiss army knife. Genome Biol. 2004, 5: 218- 10.1186/gb-2004-5-4-218
Timm DE, Mueller HA, Bhanumoorthy P, Harp JM, Bunick GJ: Crystal structure and mechanism of a carbon-carbon bond hydrolase. Structure Fold Des. 1999, 7: 1023-1033. 10.1016/S0969-2126(99)80170-1
Tremblay S, Khandjian EW: Successful use of long-term frozen lymphocytes for the establishment of lymphoblastoid cell lines. Clin Biochem. 1998, 31: 555-556. 10.1016/S0009-9120(98)00066-6
Bergeron A, D'Astous M, Timm DE, Tanguay RM: Structural and functional analysis of missense mutations in fumarylacetoacetate hydrolase, the gene deficient in hereditary tyrosinemia type 1. J Biol Chem. 2001, 276: 15225-15231. 10.1074/jbc.M009341200
Bazin R, Lemieux R: Increased proportion of B cell hybridomas secreting monoclonal antibodies of desired specificity in cultures containing macrophage-derived hybridoma growth factor (IL-6). J Immunol Methods. 1989, 116: 245-249. 10.1016/0022-1759(89)90210-X